Hostname: page-component-78c5997874-xbtfd Total loading time: 0 Render date: 2024-10-30T18:07:00.301Z Has data issue: false hasContentIssue false

A multicentre, double-blind, randomized comparison of quetiapine (ICI 204,636, ‘Seroquel’) and haloperidol in schizophrenia

Published online by Cambridge University Press:  01 January 2000

D. L. COPOLOV
Affiliation:
Mental Health Research Institute of Victoria, Australia: AstraZeneca
C. G. G. LINK
Affiliation:
Mental Health Research Institute of Victoria, Australia: AstraZeneca
B. KOWALCYK
Affiliation:
Mental Health Research Institute of Victoria, Australia: AstraZeneca

Abstract

Background. Quetiapine (ICI 204,636, ‘Seroquel’) is a new atypical antipsychotic agent with a similar binding profile to the original atypical antipsychotic, clozapine. Its clinical efficacy has already been demonstrated at multiple fixed doses (150–750 mg/day) and has been suggested to be comparable with haloperidol (12 mg/day).

Methods. This international, 6-week, multicentre, double-blind, randomized, parallel-group trial compared quetiapine with haloperidol (455 mg and 8 mg mean total daily doses, respectively) in 448 hospitalized patients with acute exacerbation of chronic or subchronic schizophrenia (DSM-III-R), in order to establish their equivalence in terms of efficacy, and the nature of their tolerability profiles, especially in terms of extrapyramidal symptoms (EPS) and serum prolactin levels.

Results. Both quetiapine and haloperidol produced a clear reduction in the Positive and Negative Syndrome Scale (PANSS) scores and Clinical Global Impression (CGI) Severity of Illness and Global Improvement scores. At day 42, the PANSS total score was reduced by −18·7±1·63 in the quetiapine group, and −22·1±1·63 in the haloperidol group (P = 0·13, between-treatment).

Quetiapine was better tolerated than haloperidol in terms of EPS as demonstrated by the significant differences in the Simpson Scale and Abnormal Involuntary Movement Scale scores (P<0·05). Although patients in both groups had elevated serum prolactin concentrations at baseline, mean serum prolactin concentration decreased (by 16·5 μg/l) in quetiapine-treated patients, yet increased (by 5·9 μg/l) in patients treated with haloperidol.

Conclusion. Quetiapine is an effective and well tolerated antipsychotic of comparable efficacy to haloperidol and lacks the latter compound's effect on prolactin and EPS.

Type
Research Article
Copyright
© 2000 Cambridge University Press

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)